Oncology Early Phase / Multiple Disease Site Hematologic Malignancies Early Phase Team Leukemia AML Relapsed/Refractory Exhausted all SOC options
Categories
Protocols
JNJ-75276617ALE1001 Phase I OPEN TO ACCRUAL
A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia